HEADER VIRAL PROTEIN/IMMUNE SYSTEM 17-FEB-21 7LRS TITLE CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE IN COMPLEX WITH NEUTRALIZING TITLE 2 ANTIBODY A23-58.1 THAT TARGETS THE RECEPTOR-BINDING DOMAIN COMPND MOL_ID: 1; COMPND 2 MOLECULE: SPIKE GLYCOPROTEIN; COMPND 3 CHAIN: C; COMPND 4 FRAGMENT: RECEPTOR BINDING DOMAIN (UNP RESIDUES 332-527); COMPND 5 SYNONYM: SPIKE PROTEIN S1; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: ANTIBODY A23-58.1 HEAVY CHAIN; COMPND 9 CHAIN: D; COMPND 10 ENGINEERED: YES; COMPND 11 MOL_ID: 3; COMPND 12 MOLECULE: ANTIBODY A23-58.1 LIGHT CHAIN; COMPND 13 CHAIN: E; COMPND 14 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS SOURCE 3 2; SOURCE 4 ORGANISM_COMMON: 2019-NCOV, SARS-COV-2; SOURCE 5 ORGANISM_TAXID: 2697049; SOURCE 6 GENE: S, 2; SOURCE 7 EXPRESSION_SYSTEM: HOMO SAPIENS; SOURCE 8 EXPRESSION_SYSTEM_COMMON: HUMAN; SOURCE 9 EXPRESSION_SYSTEM_TAXID: 9606; SOURCE 10 EXPRESSION_SYSTEM_CELL_LINE: HEK 293F; SOURCE 11 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 12 EXPRESSION_SYSTEM_PLASMID: PVRC8400; SOURCE 13 MOL_ID: 2; SOURCE 14 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 15 ORGANISM_COMMON: HUMAN; SOURCE 16 ORGANISM_TAXID: 9606; SOURCE 17 EXPRESSION_SYSTEM: HOMO SAPIENS; SOURCE 18 EXPRESSION_SYSTEM_COMMON: HUMAN; SOURCE 19 EXPRESSION_SYSTEM_TAXID: 9606; SOURCE 20 MOL_ID: 3; SOURCE 21 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 22 ORGANISM_COMMON: HUMAN; SOURCE 23 ORGANISM_TAXID: 9606; SOURCE 24 EXPRESSION_SYSTEM: HOMO SAPIENS; SOURCE 25 EXPRESSION_SYSTEM_COMMON: HUMAN; SOURCE 26 EXPRESSION_SYSTEM_TAXID: 9606 KEYWDS SARS-COV-2, RECEPTOR-BINDING DOMAIN, ANTIBODY, VIRAL PROTEIN-IMMUNE KEYWDS 2 SYSTEM COMPLEX EXPDTA ELECTRON MICROSCOPY AUTHOR T.ZHOU,Y.TSYBOVSKY REVDAT 3 13-NOV-24 7LRS 1 REMARK REVDAT 2 25-AUG-21 7LRS 1 JRNL REVDAT 1 14-JUL-21 7LRS 0 JRNL AUTH L.WANG,T.ZHOU,Y.ZHANG,E.S.YANG,C.A.SCHRAMM,W.SHI,A.PEGU, JRNL AUTH 2 O.K.OLONINIYI,A.R.HENRY,S.DARKO,S.R.NARPALA,C.HATCHER, JRNL AUTH 3 D.R.MARTINEZ,Y.TSYBOVSKY,E.PHUNG,O.M.ABIONA,A.ANTIA, JRNL AUTH 4 E.M.CALE,L.A.CHANG,M.CHOE,K.S.CORBETT,R.L.DAVIS, JRNL AUTH 5 A.T.DIPIAZZA,I.J.GORDON,S.H.HAIT,T.HERMANUS,P.KGAGUDI, JRNL AUTH 6 F.LABOUNE,K.LEUNG,T.LIU,R.D.MASON,A.F.NAZZARI,L.NOVIK, JRNL AUTH 7 S.O'CONNELL,S.O'DELL,A.S.OLIA,S.D.SCHMIDT,T.STEPHENS, JRNL AUTH 8 C.D.STRINGHAM,C.A.TALANA,I.T.TENG,D.A.WAGNER,A.T.WIDGE, JRNL AUTH 9 B.ZHANG,M.ROEDERER,J.E.LEDGERWOOD,T.J.RUCKWARDT, JRNL AUTH10 M.R.GAUDINSKI,P.L.MOORE,N.A.DORIA-ROSE,R.S.BARIC,B.S.GRAHAM, JRNL AUTH11 A.B.MCDERMOTT,D.C.DOUEK,P.D.KWONG,J.R.MASCOLA,N.J.SULLIVAN, JRNL AUTH12 J.MISASI JRNL TITL ULTRAPOTENT ANTIBODIES AGAINST DIVERSE AND HIGHLY JRNL TITL 2 TRANSMISSIBLE SARS-COV-2 VARIANTS. JRNL REF SCIENCE V. 373 2021 JRNL REFN ESSN 1095-9203 JRNL PMID 34210892 JRNL DOI 10.1126/SCIENCE.ABH1766 REMARK 2 REMARK 2 RESOLUTION. 3.89 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 SOFTWARE PACKAGES : CRYOSPARC, COOT, PHENIX, CRYOSPARC REMARK 3 RECONSTRUCTION SCHEMA : FOURIER SPACE REMARK 3 REMARK 3 EM MAP-MODEL FITTING AND REFINEMENT REMARK 3 PDB ENTRY : 7KMS REMARK 3 REFINEMENT SPACE : REAL REMARK 3 REFINEMENT PROTOCOL : OTHER REMARK 3 REFINEMENT TARGET : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE : NULL REMARK 3 REMARK 3 FITTING PROCEDURE : NULL REMARK 3 REMARK 3 EM IMAGE RECONSTRUCTION STATISTICS REMARK 3 NOMINAL PIXEL SIZE (ANGSTROMS) : NULL REMARK 3 ACTUAL PIXEL SIZE (ANGSTROMS) : NULL REMARK 3 EFFECTIVE RESOLUTION (ANGSTROMS) : 3.890 REMARK 3 NUMBER OF PARTICLES : 123016 REMARK 3 CTF CORRECTION METHOD : PHASE FLIPPING AND AMPLITUDE REMARK 3 CORRECTION REMARK 3 REMARK 3 EM RECONSTRUCTION MAGNIFICATION CALIBRATION: NULL REMARK 3 REMARK 3 OTHER DETAILS: NULL REMARK 4 REMARK 4 7LRS COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 17-FEB-21. REMARK 100 THE DEPOSITION ID IS D_1000254852. REMARK 245 REMARK 245 EXPERIMENTAL DETAILS REMARK 245 RECONSTRUCTION METHOD : SINGLE PARTICLE REMARK 245 SPECIMEN TYPE : NULL REMARK 245 REMARK 245 ELECTRON MICROSCOPE SAMPLE REMARK 245 SAMPLE TYPE : PARTICLE REMARK 245 PARTICLE TYPE : POINT REMARK 245 NAME OF SAMPLE : SARS-COV-2 SPIKE IN COMPLEX REMARK 245 WITH NEUTRALIZING ANTIBODY A789- REMARK 245 58.1 REMARK 245 SAMPLE CONCENTRATION (MG ML-1) : 0.50 REMARK 245 SAMPLE SUPPORT DETAILS : NULL REMARK 245 SAMPLE VITRIFICATION DETAILS : BLOT FOR 1.5 SECONDS BEFORE REMARK 245 PLUGGING. REMARK 245 SAMPLE BUFFER : NULL REMARK 245 PH : 7.40 REMARK 245 SAMPLE DETAILS : THE COMPLEX WAS PREPARED BY REMARK 245 MIXING SARS-COV-2 SPIKE PROTEIN AND FAB FRAGMENT OF ANTIBODY REMARK 245 A789-58.1 AT A MOLAR RATIO OF 1:3.6. REMARK 245 REMARK 245 DATA ACQUISITION REMARK 245 DATE OF EXPERIMENT : NULL REMARK 245 NUMBER OF MICROGRAPHS-IMAGES : NULL REMARK 245 TEMPERATURE (KELVIN) : NULL REMARK 245 MICROSCOPE MODEL : FEI TITAN KRIOS REMARK 245 DETECTOR TYPE : OTHER REMARK 245 MINIMUM DEFOCUS (NM) : 1100.00 REMARK 245 MAXIMUM DEFOCUS (NM) : 2100.00 REMARK 245 MINIMUM TILT ANGLE (DEGREES) : NULL REMARK 245 MAXIMUM TILT ANGLE (DEGREES) : NULL REMARK 245 NOMINAL CS : 2.70 REMARK 245 IMAGING MODE : BRIGHT FIELD REMARK 245 ELECTRON DOSE (ELECTRONS NM**-2) : 4000.00 REMARK 245 ILLUMINATION MODE : FLOOD BEAM REMARK 245 NOMINAL MAGNIFICATION : 105000 REMARK 245 CALIBRATED MAGNIFICATION : NULL REMARK 245 SOURCE : FIELD EMISSION GUN REMARK 245 ACCELERATION VOLTAGE (KV) : 300 REMARK 245 IMAGING DETAILS : NULL REMARK 247 REMARK 247 ELECTRON MICROSCOPY REMARK 247 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM ELECTRON REMARK 247 MICROSCOPY DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE REMARK 247 THAT CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES REMARK 247 ON THESE RECORDS ARE MEANINGLESS EXCEPT FOR THE CALCULATION REMARK 247 OF THE STRUCTURE FACTORS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D, E, A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 SER D 128 REMARK 465 LYS D 129 REMARK 465 SER D 130 REMARK 465 THR D 131 REMARK 465 SER D 132 REMARK 465 GLY D 133 REMARK 465 GLY D 134 REMARK 465 LYS D 214 REMARK 465 SER D 215 REMARK 465 CYS D 216 REMARK 465 ASP D 217 REMARK 465 LYS D 218 REMARK 465 GLU E 213 REMARK 465 CYS E 214 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 SER D 113 OG REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OD2 ASP E 82 OH TYR E 86 2.18 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR C 333 -155.28 46.50 REMARK 500 ALA C 348 175.01 178.18 REMARK 500 TYR C 365 49.80 -82.68 REMARK 500 TYR C 380 152.45 -46.73 REMARK 500 GLN C 414 148.90 67.32 REMARK 500 ASN C 487 26.78 47.23 REMARK 500 SER C 514 -169.32 -160.40 REMARK 500 LYS D 12 -168.84 -127.59 REMARK 500 SER D 54 139.78 73.56 REMARK 500 ARG D 66 -3.17 68.70 REMARK 500 ASP D 72 148.57 67.01 REMARK 500 ALA D 88 -169.63 -160.44 REMARK 500 ASN D 99 -94.95 58.87 REMARK 500 ASN D 155 -3.50 67.89 REMARK 500 GLN D 192 -172.97 67.21 REMARK 500 LYS D 201 -34.10 -143.03 REMARK 500 ASN D 204 67.67 -100.59 REMARK 500 ALA E 51 -70.66 63.46 REMARK 500 SER E 53 -169.03 -167.87 REMARK 500 ALA E 55 -167.27 -78.93 REMARK 500 ALA E 84 -169.18 -162.62 REMARK 500 VAL E 110 97.64 35.10 REMARK 500 ASN E 138 64.95 60.37 REMARK 500 SER E 202 -111.32 55.33 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: EMD-23498 RELATED DB: EMDB REMARK 900 RELATED ID: EMD-23499 RELATED DB: EMDB REMARK 900 FULL SPIKE WITH ANTIBODY REMARK 900 RELATED ID: 7LRT RELATED DB: PDB REMARK 900 FULL SPIKE WITH ANTIBODY REMARK 900 RELATED ID: EMD-23915 RELATED DB: EMDB REMARK 900 STRUCTURE FROM SAME CLASS MEMBER DBREF 7LRS C 332 527 UNP P0DTC2 SPIKE_SARS2 332 527 DBREF 7LRS D 1 218 PDB 7LRS 7LRS 1 218 DBREF 7LRS E 1 214 PDB 7LRS 7LRS 1 214 SEQRES 1 C 196 ILE THR ASN LEU CYS PRO PHE GLY GLU VAL PHE ASN ALA SEQRES 2 C 196 THR ARG PHE ALA SER VAL TYR ALA TRP ASN ARG LYS ARG SEQRES 3 C 196 ILE SER ASN CYS VAL ALA ASP TYR SER VAL LEU TYR ASN SEQRES 4 C 196 SER ALA SER PHE SER THR PHE LYS CYS TYR GLY VAL SER SEQRES 5 C 196 PRO THR LYS LEU ASN ASP LEU CYS PHE THR ASN VAL TYR SEQRES 6 C 196 ALA ASP SER PHE VAL ILE ARG GLY ASP GLU VAL ARG GLN SEQRES 7 C 196 ILE ALA PRO GLY GLN THR GLY LYS ILE ALA ASP TYR ASN SEQRES 8 C 196 TYR LYS LEU PRO ASP ASP PHE THR GLY CYS VAL ILE ALA SEQRES 9 C 196 TRP ASN SER ASN ASN LEU ASP SER LYS VAL GLY GLY ASN SEQRES 10 C 196 TYR ASN TYR LEU TYR ARG LEU PHE ARG LYS SER ASN LEU SEQRES 11 C 196 LYS PRO PHE GLU ARG ASP ILE SER THR GLU ILE TYR GLN SEQRES 12 C 196 ALA GLY SER THR PRO CYS ASN GLY VAL GLU GLY PHE ASN SEQRES 13 C 196 CYS TYR PHE PRO LEU GLN SER TYR GLY PHE GLN PRO THR SEQRES 14 C 196 ASN GLY VAL GLY TYR GLN PRO TYR ARG VAL VAL VAL LEU SEQRES 15 C 196 SER PHE GLU LEU LEU HIS ALA PRO ALA THR VAL CYS GLY SEQRES 16 C 196 PRO SEQRES 1 D 228 GLN MET GLN LEU VAL GLN SER GLY PRO GLU VAL LYS LYS SEQRES 2 D 228 PRO GLY THR SER VAL LYS VAL SER CYS LYS ALA SER GLY SEQRES 3 D 228 PHE THR PHE THR SER SER ALA VAL GLN TRP VAL ARG GLN SEQRES 4 D 228 ALA ARG GLY GLN ARG LEU GLU TRP ILE GLY TRP ILE VAL SEQRES 5 D 228 VAL GLY SER GLY ASN THR ASN TYR ALA GLN LYS PHE GLN SEQRES 6 D 228 GLU ARG VAL THR ILE THR ARG ASP MET SER THR SER THR SEQRES 7 D 228 ALA TYR MET GLU LEU SER SER LEU ARG SER GLU ASP THR SEQRES 8 D 228 ALA VAL TYR TYR CYS ALA ALA PRO ASN CYS SER ASN VAL SEQRES 9 D 228 VAL CYS TYR ASP GLY PHE ASP ILE TRP GLY GLN GLY THR SEQRES 10 D 228 MET VAL THR VAL SER SER ALA SER THR LYS GLY PRO SER SEQRES 11 D 228 VAL PHE PRO LEU ALA PRO SER SER LYS SER THR SER GLY SEQRES 12 D 228 GLY THR ALA ALA LEU GLY CYS LEU VAL LYS ASP TYR PHE SEQRES 13 D 228 PRO GLU PRO VAL THR VAL SER TRP ASN SER GLY ALA LEU SEQRES 14 D 228 THR SER GLY VAL HIS THR PHE PRO ALA VAL LEU GLN SER SEQRES 15 D 228 SER GLY LEU TYR SER LEU SER SER VAL VAL THR VAL PRO SEQRES 16 D 228 SER SER SER LEU GLY THR GLN THR TYR ILE CYS ASN VAL SEQRES 17 D 228 ASN HIS LYS PRO SER ASN THR LYS VAL ASP LYS LYS VAL SEQRES 18 D 228 GLU PRO LYS SER CYS ASP LYS SEQRES 1 E 215 GLU ILE VAL LEU THR GLN SER PRO GLY THR LEU SER LEU SEQRES 2 E 215 SER PRO GLY GLU ARG ALA THR LEU SER CYS ARG ALA SER SEQRES 3 E 215 GLN SER VAL SER SER SER TYR LEU ALA TRP TYR GLN GLN SEQRES 4 E 215 LYS PRO GLY GLN ALA PRO ARG LEU LEU ILE TYR SER ALA SEQRES 5 E 215 SER SER ARG ALA THR GLY ILE PRO ASP ARG PHE SER GLY SEQRES 6 E 215 SER GLY SER GLY THR ASP PHE THR LEU THR ILE SER ARG SEQRES 7 E 215 LEU GLU PRO GLU ASP PHE ALA VAL TYR PHE CYS GLN GLN SEQRES 8 E 215 TYR GLY THR SER PRO TRP THR PHE GLY GLN GLY THR LYS SEQRES 9 E 215 VAL GLU ILE LYS ARG THR VAL ALA ALA PRO SER VAL PHE SEQRES 10 E 215 ILE PHE PRO PRO SER ASP GLU GLN LEU LYS SER GLY THR SEQRES 11 E 215 ALA SER VAL VAL CYS LEU LEU ASN ASN PHE TYR PRO ARG SEQRES 12 E 215 GLU ALA LYS VAL GLN TRP LYS VAL ASP ASN ALA LEU GLN SEQRES 13 E 215 SER GLY ASN SER GLN GLU SER VAL THR GLU GLN ASP SER SEQRES 14 E 215 LYS ASP SER THR TYR SER LEU SER SER THR LEU THR LEU SEQRES 15 E 215 SER LYS ALA ASP TYR GLU LYS HIS LYS VAL TYR ALA CYS SEQRES 16 E 215 GLU VAL THR HIS GLN GLY LEU SER SER PRO VAL THR LYS SEQRES 17 E 215 SER PHE ASN ARG GLY GLU CYS HET NAG A 1 14 HET NAG A 2 14 HET BMA A 3 11 HET MAN A 4 11 HET MAN A 5 11 HET NAG B 1 14 HET NAG B 2 14 HET BMA B 3 11 HETNAM NAG 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE HETNAM BMA BETA-D-MANNOPYRANOSE HETNAM MAN ALPHA-D-MANNOPYRANOSE HETSYN NAG N-ACETYL-BETA-D-GLUCOSAMINE; 2-ACETAMIDO-2-DEOXY-BETA- HETSYN 2 NAG D-GLUCOSE; 2-ACETAMIDO-2-DEOXY-D-GLUCOSE; 2-ACETAMIDO- HETSYN 3 NAG 2-DEOXY-GLUCOSE; N-ACETYL-D-GLUCOSAMINE HETSYN BMA BETA-D-MANNOSE; D-MANNOSE; MANNOSE HETSYN MAN ALPHA-D-MANNOSE; D-MANNOSE; MANNOSE FORMUL 4 NAG 4(C8 H15 N O6) FORMUL 4 BMA 2(C6 H12 O6) FORMUL 4 MAN 2(C6 H12 O6) HELIX 1 AA1 PRO C 337 ASN C 343 1 7 HELIX 2 AA2 SER C 366 SER C 371 1 6 HELIX 3 AA3 ARG D 83 THR D 87 5 5 HELIX 4 AA4 HIS E 198 SER E 202 5 5 SHEET 1 AA1 4 ARG C 357 ILE C 358 0 SHEET 2 AA1 4 VAL C 395 ILE C 402 -1 O VAL C 395 N ILE C 358 SHEET 3 AA1 4 TYR C 508 LEU C 513 -1 O VAL C 512 N ASP C 398 SHEET 4 AA1 4 VAL C 433 TRP C 436 -1 N ILE C 434 O VAL C 511 SHEET 1 AA2 2 LEU C 452 ARG C 454 0 SHEET 2 AA2 2 LEU C 492 SER C 494 -1 O GLN C 493 N TYR C 453 SHEET 1 AA3 4 GLN D 3 GLN D 6 0 SHEET 2 AA3 4 VAL D 20 SER D 25 -1 O LYS D 23 N VAL D 5 SHEET 3 AA3 4 TYR D 79 LEU D 82 -1 O MET D 80 N VAL D 20 SHEET 4 AA3 4 VAL D 67 THR D 68 -1 N THR D 68 O GLU D 81 SHEET 1 AA4 2 GLU D 10 LYS D 12 0 SHEET 2 AA4 2 VAL D 109 VAL D 111 1 O THR D 110 N LYS D 12 SHEET 1 AA5 3 ALA D 33 TRP D 36 0 SHEET 2 AA5 3 GLY D 49 VAL D 52 -1 O GLY D 49 N TRP D 36 SHEET 3 AA5 3 THR D 57 TYR D 59 -1 O ASN D 58 N TRP D 50 SHEET 1 AA6 2 ARG D 38 GLN D 39 0 SHEET 2 AA6 2 VAL D 89 TYR D 90 -1 O VAL D 89 N GLN D 39 SHEET 1 AA7 2 ALA D 93 ALA D 94 0 SHEET 2 AA7 2 ILE D 102 TRP D 103 -1 O ILE D 102 N ALA D 94 SHEET 1 AA8 2 CYS D 97 SER D 98 0 SHEET 2 AA8 2 VAL D 100A CYS D 100B-1 O VAL D 100A N SER D 98 SHEET 1 AA9 4 SER D 120 LEU D 124 0 SHEET 2 AA9 4 ALA D 137 TYR D 145 -1 O LEU D 141 N PHE D 122 SHEET 3 AA9 4 TYR D 176 THR D 183 -1 O VAL D 182 N LEU D 138 SHEET 4 AA9 4 HIS D 164 THR D 165 -1 N HIS D 164 O VAL D 181 SHEET 1 AB1 4 SER D 120 LEU D 124 0 SHEET 2 AB1 4 ALA D 137 TYR D 145 -1 O LEU D 141 N PHE D 122 SHEET 3 AB1 4 TYR D 176 THR D 183 -1 O VAL D 182 N LEU D 138 SHEET 4 AB1 4 VAL D 169 LEU D 170 -1 N VAL D 169 O SER D 177 SHEET 1 AB2 2 THR D 151 VAL D 152 0 SHEET 2 AB2 2 VAL D 198 ASN D 199 -1 O ASN D 199 N THR D 151 SHEET 1 AB3 2 THR E 10 SER E 12 0 SHEET 2 AB3 2 LYS E 103 GLU E 105 1 O LYS E 103 N LEU E 11 SHEET 1 AB4 2 THR E 20 SER E 22 0 SHEET 2 AB4 2 THR E 72 THR E 74 -1 O LEU E 73 N LEU E 21 SHEET 1 AB5 3 ARG E 45 TYR E 49 0 SHEET 2 AB5 3 LEU E 33 GLN E 38 -1 N GLN E 37 O ARG E 45 SHEET 3 AB5 3 VAL E 85 GLN E 90 -1 O PHE E 87 N TYR E 36 SHEET 1 AB6 4 SER E 114 PHE E 118 0 SHEET 2 AB6 4 VAL E 132 PHE E 139 -1 O VAL E 133 N PHE E 118 SHEET 3 AB6 4 TYR E 173 LEU E 179 -1 O LEU E 175 N LEU E 136 SHEET 4 AB6 4 SER E 159 VAL E 163 -1 N GLN E 160 O THR E 178 SHEET 1 AB7 2 LYS E 145 TRP E 148 0 SHEET 2 AB7 2 CYS E 194 THR E 197 -1 O GLU E 195 N GLN E 147 SSBOND 1 CYS C 336 CYS C 361 1555 1555 2.03 SSBOND 2 CYS C 379 CYS C 432 1555 1555 2.03 SSBOND 3 CYS C 391 CYS C 525 1555 1555 2.03 SSBOND 4 CYS C 480 CYS C 488 1555 1555 2.03 SSBOND 5 CYS D 22 CYS D 92 1555 1555 2.03 SSBOND 6 CYS D 97 CYS D 100B 1555 1555 2.03 SSBOND 7 CYS D 140 CYS D 196 1555 1555 2.04 SSBOND 8 CYS E 23 CYS E 88 1555 1555 2.03 SSBOND 9 CYS E 134 CYS E 194 1555 1555 2.04 LINK ND2 ASN C 343 C1 NAG A 1 1555 1555 1.44 LINK ND2 ASN D 96 C1 NAG B 1 1555 1555 1.44 LINK O4 NAG A 1 C1 NAG A 2 1555 1555 1.44 LINK O4 NAG A 2 C1 BMA A 3 1555 1555 1.44 LINK O3 BMA A 3 C1 MAN A 4 1555 1555 1.45 LINK O6 BMA A 3 C1 MAN A 5 1555 1555 1.45 LINK O4 NAG B 1 C1 NAG B 2 1555 1555 1.44 LINK O4 NAG B 2 C1 BMA B 3 1555 1555 1.44 CISPEP 1 SER E 94 PRO E 95 0 -5.31 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000